For the interim period of the fiscal year ending March 2027, consolidated net sales were 17,568 million yen, up 19.0% year-on-year, and operating income rose significantly to 1,555 million yen. Interim net income attributable to owners of parent was 2,197 million yen, mainly due to increased overseas orders and contributions from the CRO business. Full-year forecasts for FY2027 remain unchanged. Dividends assume an interim dividend of 20 yen and a full-year total of 50 yen.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"2395","jir_company_name":"Shin Nippon Biomedical Laboratories, Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-10","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/2395-20261110-01.pdf","jir_short_summary":"For the interim period of the fiscal year ending March 2027, consolidated net sales were 17,568 million yen, up 19.0% year-on-year, and operating income rose significantly to 1,555 million yen. Interim net income attributable to owners of parent was 2,197 million yen, mainly due to increased overseas orders and contributions from the CRO business. Full-year forecasts for FY2027 remain unchanged. Dividends assume an interim dividend of 20 yen and a full-year total of 50 yen.","jir_summary":"### Summary of Results\nShin Nippon Biomedical Laboratories, Ltd. centered on its CRO business achieved record interim net sales of 17,568 million yen, a 19.0% increase year-on-year. Operating income rose substantially to 1,555 million yen, ordinary income reached 3,081 million yen, and interim net income attributable to owners of parent expanded to 2,197 million yen. Contributing factors included timing shifts in revenue recognition within the CRO business and deferral of expenses in the TR business, along with increased global orders. The growing proportion of overseas operations and costs related to product development by Satsuma Co. also had an impact.\n\n### Forward Policy and Financial Position\nThrough supplementary financial materials and an earnings briefing, the company maintained its full-year forecasts for the fiscal year ending March 2027 while monitoring foreign exchange trends and the effects of timing differences. On the financial side, total assets were 109,364 million yen, equity ratio was 36.1%, and shareholders' equity was 39,818 million yen, maintaining stability. In the financial notice, the dividend policy assumes a year-end dividend of 20 yen and a full-year total of 50 yen, with no change to dividend forecasts. Cash and cash equivalents increased to 24,270 million yen at the interim period end.","jir_financial_highlights":"Net Sales: 17,568 million yen (Year-over-Year +19.0%)\nOperating Income: 1,555 million yen (Year-over-Year +1,506 million yen (+3054.0%))\nOrdinary Income: 3,081 million yen (Year-over-Year +1,453 million yen (+89.3%))\nNet Income Attributable to Owners of Parent (Interim): 2,197 million yen (Year-over-Year +1,136 million yen (+107.1%))\nTotal Assets: 109,364 million yen (Compared to previous consolidated fiscal year-end +4,308 million yen (+4.1%))","jir_category":"","jir_hashtags":"#ShinNipponBiomedicalLaboratories, #Earnings, #Interim","jir_key_figures":"Net Sales: 17,568 million yen (Year-over-Year +19.0%)\nOperating Income: 1,555 million yen (Year-over-Year +)\nNet Income Attributable to Owners of Parent (Interim): 2,197 million yen (Year-over-Year +107.1%)","jir_meta_title":"Shin Nippon Biomedical Laboratories, Ltd. | FY2027 Q2 Financial Summary \u2013 Strong Sales of 17,568 million yen and Significant Profit Growth","jir_meta_description":"Shin Nippon Biomedical Laboratories, Ltd. reported FY2027 Q2 consolidated net sales of 17,568 million yen, operating income of 1,555 million yen, and net income of 2,197 million yen. Improved profitability in the CRO business and progress in the TR business supported results. Full-year forecasts remain unchanged, with dividends assumed at 50 yen.","jir_og_title":"Shin Nippon Biomedical Laboratories, Ltd. | FY2027 Interim Results: Record Net Sales and Continued Profit Growth","jir_og_description":"In FY2027 interim results, Shin Nippon Biomedical Laboratories, Ltd. posted record net sales of 17,568 million yen, operating income of 1,555 million yen, and net income of 2,197 million yen. Outlook and dividend policy were also disclosed.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":17048,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-145945","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n